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Abstract 
Background: Idiopathic pulmonary fibrosis (IPF) is a complex disease with a highly 
variable clinical course and generally poor prognosis. Classified as a rare disease, 
significant increases in incidence have been recorded worldwide in recent years. Left 
untreated IPF is extremely debilitating with substantial personal, social and economic 
implications.  
Objectives: To discuss how IPF is diagnosed and managed in real life clinical practice 
with particular reference to Italy and to determine how new and effective therapies 
can be incorporated into a patient-centred management approach in order to improve 
the lives of patients with IPF. 
Outcomes: Barriers to early diagnosis are discussed. Cited reasons for delays in 
diagnosing IPF in Italy include: inherent difficulties in diagnosis; lack of 
knowledge/awareness of the condition among point-of-contact healthcare 
professionals; delays in referral to centres of excellence and underestimation of 
symptoms by both patients and healthcare workers. Valid therapeutic options with 
demonstrated efficacy in slowing the decline in lung function are now available for 
patients with IPF. The ASCEND trial confirmed the effects of pirfenidone, approved for 
the treatment of IPF on the basis of the four phase III trials. Nintedanib, a tyrosine 
kinase inhibitor that targets the PDGF receptors α/β, FGF receptors 1 to 3, and VEGF 
receptors 1-3, is approved in the USA and the EU for the treatment of IPF. The 
TOMORROW and the INPULSIS placebo controlled trials in patients with IPF confirm the 
efficacy and safety of nintedanib and recent interim analyses endorse its long-term 
effects in slowing disease progression.  
Conclusions: The importance of early and accurate diagnosis of IPF cannot be 
underestimated and it is the duty of all healthcare professionals to be vigilant to the 
symptoms of IPF and to involve a multidisciplinary team in diagnosing and managing 
IPF early in the course of disease. 
 
Key words: Idiopathic pulmonary fibrosis, pirfenidone, nintedanib, TOMORROW, 
INPULSIS, diagnosis 
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1.1 Introduction 
 
Idiopathic pulmonary fibrosis (IPF), a chronic progressive interstitial lung disease (ILD), 
is characterized by breathlessness (initially only on exertion) and dry cough that 
interfere with daily activities. Other features include bibasilar inspiratory crackles, 
deteriorating pulmonary function tests and finger clubbing [1,2,3]. It is an extremely 
complex disease with a highly variable clinical course. Progression may take a number 
of forms — slow worsening of the severity of dyspnoea, rapid deterioration and 
progression to death or relative stability interposed with periods of acute respiratory 
decline sometimes manifest by hospitalizations for respiratory failure [4,5]. Over time 
there is an irreversible loss of lung function with median survival around three years 
from diagnosis [6].  
Although the exact mechanisms underlying the development of IPF remain elusive, it is 
thought that repetitive lung injury, such as that associated with cigarette smoke, 
industrial dusts, gastro oesophageal reflux and viral infection, leads to alveolar 
epithelial cell injury and activation [2,3,7,8]. This results in the recruitment, 
proliferation and activation of mesenchymal cells and the formation of fibroblastic foci 
and abnormal accumulation of extracellular matrix (ECM) that mirror abnormal wound 
repair. Abnormal extracellular matrix deposition and excessive collagen accumulation 
cause progressive fibrosis and stiffening of the lungs. Beyond these cellular and tissue 
changes there is evidence that growth factors including platelet-derived growth factor 
(PDGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF) 
play a role in the development and progression of IPF [9,10]. Not all individuals 
exposed to these stimuli go on to develop IPF, suggesting that affected individuals may 
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be predisposed to the condition, possibly influenced by genetic abnormalities and 
aging.  
 
The publication of international, evidence-based guidelines for the diagnosis and 
management of IPF represented a major step forward as did the introduction of new 
treatments with demonstrated efficacy and tolerability that modify symptoms and alter 
disease course. The goals of this review are multifold: to review up-to-date information 
on the incidence/prevalence of IPF with particular reference to Italy; to discuss how IPF 
is diagnosed and managed in real life clinical practice and to determine how new and 
effective therapies can be incorporated into a patient-centred management approach 
in order to improve the lives of our patients.  
 
2.1 Idiopathic pulmonary fibrosis: burden of illness 
Although IPF is classified as a rare disease, it accounts for 17–37% of all interstitial lung 
disease (ILD) and its social, healthcare and economic implications are significant [11,6]. 
Data on the prevalence and incidence of IPF remain unclear, mainly because of the lack 
of a consistent definition as well as the different diagnostic methods used. A US study 
reported the prevalence of IPF was 2.7 cases per 100,000 in those aged 35–44 years old 
and 175/100,000 in those over the age of 75 years [12,3]. On the other hand, a recent 
study on US Medicare beneficiaries from 2001–2011 showed higher rates with a 
prevalence of 494.5/100 000 in 2011. Prevalence increased annually, even in the 
subgroups based on more restrictive algorithms for diagnosis [13]. In the United 
Kingdom the incidence of and registered deaths from IPF continues to rise — at present 
there are about 15,000 patients with a diagnosis of IPF and because of its poor 
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prognosis 5000 deaths per year [11,14].  
 
Historically, the epidemiology of IPF in Italy has been a neglected area of research but 
two recent studies — one conducted in the Central-South and one in the North —
provided much needed up-to-date information [15,16]. In the Lazio study (6 million 
inhabitants) the annual prevalence and incidence of IPF were estimated at 
25.6/100,000 and 7.5/100,000 using the ICD9-CM code 516.3 without chart audit and 
31.6/100,000 and 9.3/100,000 for the IPF ‘confident’ definition after hospital chart 
[15]. In the study conducted in Lombardy (10 million inhabitants) depending on the 
algorithms used (generic, broad and narrow case definition) prevalence rates of 35.5, 
22.4, and 12.6/100,000 person-years were recorded with an observed increase in 
prevalence over the years [16]. These data confirm that in Italy as in other countries, 
the incidence of IPF is increasing with rates and regrettably prognosis, similar to those 
of some forms of cancer.  
 
The growing incidence, the variability and irreversibility of its clinical course, as well its 
inevitable progression mean that antifibrotic therapy should be discussed with patients 
in a timely manner after first diagnosis. However, obtaining an early and accurate 
diagnosis of IPF is not straightforward and necessitates the collaborative expertise of a 
multidisciplinary team (MDT) including respiratory physicians, radiologists and 
histopathologists. 
 
3.1 Ensuring an early and accurate diagnosis of idiopathic pulmonary fibrosis  
3.1.1 Clinical features 
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IPF should be considered in all adult patients with unexplained chronic exertional 
dyspnoea. It commonly presents with cough, bibasilar inspiratory crackles also known 
as Velcro® crackles (because the sound is similar to that produced when Velcro® is 
detached), and finger clubbing [17]. Physical examination of the chest reveals crackles 
not editable with coughing throughout the inspiratory phase. These breath sounds are 
present from the early stages of the disease and although Velcro® crackles are not 
peculiar to IPF, their presence in subjects aged ≥ 60 years, should rise the suspicion of 
IPF [17,18,19,20]. 
 
3.1.2 Radiological and histopathological features 
 The gold standard imaging test for suspected IPF is high-resolution computed 
tomography (HRCT), which should be carried out as early as possible after symptoms 
first appear. The new international diagnostic criteria for radiology and histopathology 
are more precise than previous versions and include three HRCT categories: usual 
interstitial pneumonia (UIP), possible UIP and inconsistent with UIP patterns and four 
histological categories: UIP, probable UIP, possible UIP and not UIP [2,17] (Tables 1 and 
2).  
 
Table 1. High-resolution computed tomography criteria for usual interstitial pneumonia 
(UIP) pattern in idiopathic pulmonary fibrosis (IPF)  
 
UIP Pattern - All Four Features 
1 Subpleural, basal predominance 
2 Reticular abnormality 
3 Honeycombing with or without traction bronchiectasis 
4 Absence of features listed as inconsistent with UIP pattern 
Possible UIP Pattern - All Three Features 
1 Subpleural, basal predominance 
2 Reticular abnormality 
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3 Absence of features listed as inconsistent with UIP pattern 
Inconsistent with UIP Pattern - Any of the Seven Features 
1 Upper or mid-lung predominance 
2 Peribronchovascular predominance 
3 Extensive ground glass abnormality (extent > reticular abnormality) 
4 Profuse micronodules (bilateral, predominantly upper lobes) 
5 Discrete cysts (multiple, bilateral, away from areas of honeycombing) 
6 Diffuse mosaic attenuation/air-trapping (bilateral, in three or more lobes) 
7 Consolidation in bronchopulmonary segment(s)/lobe(s) 
Reprinted with permission of the American Thoracic Society. Copyright © 2016 American Thoracic Society. 
G. Raghu et al. 2011 An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based 
guidelines for diagnosis and management. Am J Respir Crit Care Med 183, 6 788–824. 
The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic 
Society. 
 
Table 2. Histological criteria for usual interstitial pneumonia (UIP) pattern in idiopathic 
pulmonary fibrosis (IPF) 
 
UIP Pattern (All Four 
Criteria) 
Probable UIP 
Pattern 
 
Possible UIP 
Pattern 
(All Three Criteria) 
Not UIP Pattern 
(Any of the Six 
Criteria) 
d Evidence of marked 
fibrosis/architectural 
distortion, ± 
honeycombing in a 
predominantly 
subpleural/paraseptal 
distribution  
d Presence of patchy 
involvement of lung 
parenchyma by 
fibrosis  
d Presence of 
fibroblast foci  
d Absence of features 
against a diagnosis of 
UIP suggesting an 
alternate diagnosis 
(see fourth column) 
d Evidence of 
marked fibrosis / 
architectural 
distortion, ± 
honeycombing  
d Absence of 
either patchy 
involvement or 
fibroblastic foci, 
but not both  
d Absence of 
features against a 
diagnosis of UIP 
suggesting an 
alternate 
diagnosis (see 
fourth column) OR  
d Honeycomb 
changes only‡  
 
d Patchy or diffuse 
involvement of 
lung parenchyma 
by fibrosis, with or 
without interstitial 
inflammation  
d Absence of 
other criteria for 
UIP (see UIP 
PATTERN column)  
d Absence of 
features against a 
diagnosis of UIP 
suggesting an 
alternate 
diagnosis (see 
fourth column) 
d Hyaline 
membranes*  
d Organizing 
pneumonia*†  
d Granulomas†  
d Marked 
interstitial 
inflammatory cell 
infiltrate away 
from 
honeycombing  
d Predominant 
airway centered 
changes  
d Other features 
suggestive of an 
alternate 
diagnosis  
 
Reprinted with permission of the American Thoracic Society. Copyright © 2016 American Thoracic Society. 
G. Raghu et al. 2011 An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based 
guidelines for diagnosis and management. Am J Respir Crit Care Med 183, 6 788–824. 
The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic 
Society. 
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Definition of abbreviations: HRCT 5 high-resolution computed tomography; UIP 5 usual 
interstitial pneumonia. 
* Can be associated with acute exacerbation of idiopathic pumonary fibrosis. 
† An isolated or occasional granuloma and/or a mild component of organizing 
pneumonia pattern may rarely be coexisting in lung biopsies with an otherwise UIP 
pattern. 
‡ This scenario usually represents end-stage fibrotic lung disease where honeycombed 
segments have been sampled but where a UIP pattern might be present in other 
areas. Such areas are usually represented by overt honeycombing on HRCT and can be 
avoided by pre-operative targeting of biopsy sites away from these areas using HRCT. 
 
 
The presence of honeycombing with or without traction bronchiectasis can make the 
diagnosis of UIP pattern difficult using HRCT alone; further workup is required if a HRCT 
scan shows features of possible and/or inconsistent UIP patterns [17]. The presence of 
a radiological and/or histological UIP pattern is not per se sufficient to establish the 
diagnosis of IPF and a definite diagnosis requires the exclusion of other known causes 
of ILD, as well as the presence of a definite UIP pattern on chest HRCT and specific 
combinations of chest HRCT/histopathology patterns. There is evidence that patients 
with IPF can be accurately diagnosed without a surgical lung biopsy (SLB).  In fact, in 
around two thirds of cases an SLB is not required and a definitive diagnosis of IPF is 
possible based on HRCT thorax alone [21] (Table 3, Figure 1).  
 
 
 
 
 
Table 3. Combination of high-resolution computed tomography (HRCT) and surgical 
lung biopsy for the diagnosis of idiopathic pulmonary fibrosis (IPF) 
 
HRCT Pattern Surgical Lung Biopsy Pattern (When Performed) 
Diagnosis of 
IPF? 
UIP  
 
UIP or Probable UIP or Possible UIP or 
Non-classifiable fibrosis YES 
Not UIP  No 
Possible UIP UIP or Probable UIP YES 
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 Possible UIP or Non-classifiable fibrosis Probable 
Inconsistent with 
UIP 
Not UIP No 
UIP  Possible 
Probable UIP or Possible UIP or Non-
classifiable fibrosis or Not UIP No 
Reprinted with permission of the American Thoracic Society. Copyright © 2016 American Thoracic Society. 
G. Raghu et al. 2011 An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based 
guidelines for diagnosis and management. Am J Respir Crit Care Med 183, 6 788–824. 
The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic 
Society. 
 
 
 
 
 
 
 
 
Figure 1. Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF).  
 
 
Reprinted with permission of the American Thoracic Society. Copyright © 2016 American Thoracic Society. 
G. Raghu et al. 2011 An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based 
guidelines for diagnosis and management. Am J Respir Crit Care Med 183, 6 788–824. 
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The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic 
Society. 
 
 
Patients with suspected IPF (i.e. patients with unexplained dyspnoea on exertion 
and/or cough with evidence of interstitial lung disease [ILD]) should be carefully 
evaluated for identifiable causes of ILD. In the absence of an identifiable cause for ILD, 
an HRCT demonstrating UIP pattern is diagnostic of IPF. In the absence of UIP pattern 
on HRCT, IPF can be diagnosed by the combination of specific HRCT and 
histopathological patterns. Therefore, international guidelines advocate for 
interdisciplinary discussion of these cases.  
 
 
In patients without a biopsy the diagnosis may be established if ILD is present and HRCT 
shows a UIP pattern. When a biopsy is required, diagnosis is made based on specific 
combinations of HRCT and SLB aspects showing a UIP pattern [12,11]. Overall the use 
of SLB is in decline, as it is no longer considered to be essential in making a diagnosis 
given the high-quality evidence regarding HRCT specificity for the recognition of UIP 
pattern. The introduction of less-invasive methods, such as the transbronchial lung 
cryobiopsy (TBLCB), have the potential to transform the diagnosis of IPF in clinical 
practice as they can be used to obtain samples large enough to morphologically 
support the multidisciplinary diagnosis of interstitial lung disease [22,23]. In a recent 
literature review Ravaglia et al. concluded that in the diagnosis of interstitial lung 
diseases (ILDs) surgical lung biopsy (SLB), is associated with significant morbidity and 
mortality and also appreciable costs and that cryobiopsy is safe and has lower 
complication and mortality rates compared to SLB. TBLC might therefore, be 
considered the first diagnostic approach for obtaining tissue in ILDs, reserving the 
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surgical approach for cases in which TBLC is not diagnostic [24]. However, although the 
technique appears to be safer than surgical lung biopsy, it is not without complications. 
Casoni et al advised its safety needs to be investigated in large multicentric trials before 
it is widely adopted [25]. Bleeding and pneumothorax (reported in about 5% of cases) 
are the most often reported adverse events and the routine preventive use of a 
Fogarty catheter does not allow the real incidence of bleeding complications to be 
evaluated. Johannson et al. reasoned that the diagnostic accuracy of TBLCB cannot be 
determined given the absence of comparative studies, and while the histopathological 
and multidisciplinary discussion-based diagnostic yield of TBLCB appears high, the 
implications of pneumothorax and moderate-to-severe hemorrhage should not be 
underestimated [26]. 
 
3.1.3 Other investigations 
Bronchoalveolar lavage (BAL) is used to exclude conditions such chronic 
hypersensitivity pneumonitis (HP), sarcoidosis or connective diseases but its role in the 
diagnosis of IPF is much debated [27,28,29,30].  
 
Transbronchial lung biopsy (TBB) is useful in excluding other interstitial lung diseases 
such as sarcoidosis or malignancies and infections but neither current nor previous 
recommendations propose TBB in the diagnosis of IPF [31]. It may be that in the right 
clinical setting and with appropriate tissue sampling TBB can support a diagnosis of UIP. 
In fact it has been shown that using a novel technique for TBB – transbronchial 
cryobiopsy, the size of TBB samples were much larger than those obtained using 
forceps.  
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Serological testing for connective tissues diseases is considered to be part of routine 
diagnostic workup of IPF in most patients whether there is a manifestation of 
connective tissue disease (CTD) or not although a study by Lee et al. showed that 
circulating autoantibody positivity is no more common in patients with IPF than in 
healthy, age-similar adults, and that patients with IPF and circulating autoantibodies do 
not represent a distinct clinical phenotype. [1,2,17,32,33,34]. Nevertheless, published 
guidelines suggest serologic evaluation should be performed even in the absence of 
signs or symptoms of connective tissue disorder and should include rheumatoid factor, 
anti-cyclic citrullinated peptide (anti-CCP) and anti-nuclear antibody titre (ANA) but 
other serological tests such as anti-synthetase antibodies, creatinephosphokinase and 
aldolase, Sjogren's antibodies and scleroderma antibodies may be indicated in 
appropriate clinical cases [32]. Signs of connective tissue disorders such as arthritis, 
Raynaud's phenomenon, skin changes, abnormal oesophageal motility should be 
investigated before IPF is confirmed [2]. Finally, a number of biomarkers are under 
investigation but this field is still very much in the early stages and as yet not generally 
accessible for routine clinical use [35,36]. 
 
3.1.4 Genotypes phenotypes and comorbidities 
Different phenotypes of IPF may have different rates of progression and the existence 
of comorbidities can influence prognosis [37]. Although it was thought that IPF was a 
slowly progressive disease it may be that there is an accelerated variant phenotype. 
Combined pulmonary fibrosis and emphysema, and disproportionate pulmonary 
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hypertension in IPF may also be distinct phenotypes. Further investigation is required 
to characterise these phenotypes and to establish if there is a biological explanation for 
these phenotypes [22].  
 
Familial IPF – defined as two or more verified cases within a group of relatives 
belonging to a primary family unit – accounts for 0.5-2.0% of all cases of IPF [3,36,38]. 
Clinical features of familial IPF are the same as the sporadic form and they are 
histologically indistinguishable except the former usually has an earlier age at onset.  
 
Effective management of IPF also involves identifying and treating comorbidities to 
improve overall quality of life (QoL) and wellbeing of patients. IPF is associated with 
both respiratory and non-respiratory comorbidities. The most frequent is 
cardiovascular disease (CVD) that is more common as the disease progresses. Other 
comorbidities include pulmonary hypertension, emphysema, chronic obstructive 
pulmonary disease (COPD), sleep-related respiratory disorders, gastro-oesophageal 
reflux and lung cancer. It has been reported that the risk of developing lung cancer is 
approximately seven-times higher in patients with IPF compared to a control 
population even after adjustment for age, sex, and smoking history [39]. Although the 
reasons for this increase are not clear it has been suggested that the IPF lung is 
specifically predisposed to developing malignancy. Lung cancer has a significant impact 
on survival of patients with IPF — reducing survival by approximately 2 years [22].  
Most patients with IPF have associated comorbid conditions, which negatively affect 
functional status, quality of life, and survival. Comorbid conditions can be pulmonary or 
extrapulmonary. Pulmonary comorbidities include pulmonary hypertension, 
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emphysema, and lung cancer, while non-pulmonary conditions include venous 
thromboembolism, coronary artery disease, congestive heart failure, sleep-disordered 
breathing, gastro-oesophageal reflux disease, and anxiety or depression [40]. The 
identification and prompt treatment of comorbidities can have a significant impact on 
overall outcome [41]. IPF alone and in combination with comorbidities significantly 
impairs QoL and imposes a substantial burden on health care resources [42].  
 
 
4.1 Addressing unmet needs in idiopathic pulmonary fibrosis: importance of early 
diagnosis  
The diagnosis of IPF is often made late in the disease course for a number of reasons — 
patients may present to their physicians having had ‘non-specific’ symptoms, such as 
non-productive cough, exertional dyspnoea for months/years previously or they may 
have been diagnosed with other more common respiratory diseases such as asthma or 
COPD before IPF is finally diagnosed [43]. Kim et al. reported that 1–3 years may elapse 
between the onset of symptoms and the specialist’s assessment, while the delay in 
diagnosis can even increase up to 5 years [44]. A survey of IPF patients from five 
different European countries showed that in 58% of patients the time between disease 
onset and diagnosis was 1 year and 55% of patients interviewed had consulted at least 
three physicians before receiving the correct diagnosis [45].  
 
There is a dearth of information on how IPF is diagnosed and managed in Italy and how 
it compares with other countries. To this end we conducted an ad hoc survey among 
our group of respiratory medicine specialists working in 8 IPF authorized prescriber 
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centres in Italy. Overall there was a total of 379 patients with IPF, 101 (26.7%) of which 
were new cases diagnosed in the preceding year (box). Of these, 55% presented for the 
first time with moderate stage IPF, 30% when IPF was already severe and only 15% first 
presented with early stage. Importantly results of the survey elucidated the main 
reasons why diagnosis of IPF in Italy is delayed: inherent difficulties in diagnosis; lack of 
knowledge/awareness of the condition among point-of-contact healthcare 
professionals; delays in referral to centres of excellence and symptoms underestimated 
by both patients and healthcare workers. 
Overview of patients treated in eight IPF authorized prescriber centres in Italy 
• Total of 379 patients in 8 centres (Alessandria, Chieti, L’Aquila, Naples, Pavia, 
Parma, Rome, Sassari). 
 
• Of these 101 (26.6%) diagnosed in the previous year. 
 
• Mean overall percentage of patients who presented with early, moderate IPF or 
severe IPF were 15%, 55% and 30%, respectively. 
 
• The majority of patients presented with a honeycomb pattern on imaging.  
 
• Reasons for patients presenting at specialist centres – first visit due to 
symptoms, referred by pneumonologist, family doctor, cardiologist, radiologist, 
rheumatologist. 
 
 
Nearly half of IPF patients show a decline in FVC and the greater is the FVC decline the 
higher is the increased risk of IPF progression and mortality. It therefore follows that 
prompt interventions to slow FVC decline may help improve clinical outcomes in 
patients with IPF [46]. Until the introduction of new therapies delays in diagnosis did 
not have a significant impact on disease progression/survival. However, now that 
effective therapies are available, early diagnosis is paramount to optimize clinical 
management.  In addition, in this era of cost containment within health care systems 
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earlier diagnosis may in fact be more cost-effective as delayed diagnosis of IPF is 
associated with increased costs in terms of investigations performed [4,47].  
 
5.1  Pharmacological strategies for the management of idiopathic pulmonary 
fibrosis: shifting the paradigm  
 
The objectives of treatment in IPF are to reduce symptoms, slow/stop progression, 
prevent acute exacerbations and ultimately to prolong survival. In the past couple of 
decades major advances in our understanding of the pathogenesis of IPF have been 
made and these developments are paralleled with the introduction of pharmacological 
treatments to effectively manage the condition. Disappointing results were obtained 
previously with therapeutic agents targeting inflammatory pathways as IPF was 
considered to be a chronic inflammatory response resulting in progressive pulmonary 
fibrosis. More recently, agents targeting the biological process that drive fibrosis have 
been shown to be effective in IPF. We have seen that VEGF, FGF and PDGF, mediate 
fibrogenesis and angiogenesis, and are hence implicated in the pathogenesis of IPF.  
 
Pirfenidone an oral antifibrotic agent was approved for the treatment of IPF in Japan, 
Europe, India, and Canada on the basis of the international phase III trials but due to 
the conflicting results of the Clinical Studies Assessing Pirfenidone in Idiopathic 
Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes (CAPACITY) trials, the US 
FDA requested a further confirmatory trial [48]. Results of the Assessment of 
Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND) 
trial in 555 patients with IPF, randomized to receive either pirfenidone or placebo 
provided confirmation of its effects [49,50,51]. A retrospective real-life study in major 
ILD centres in Italy, evaluated the effect of pirfenidone on disease progression in 128 
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patients with IPF (48 mild, 64 moderate IPF and 8 severe). Decline in lung function, 
monitored during one-year treatment with pirfenidone was compared with the decline 
measured during the one-year pre-treatment period [51]. At baseline (first pirfenidone 
prescription), mean percentage forced vital capacity (FVC) was 75% (35-143%) of 
predicted, and mean percentage diffuse lung capacity (DLCO) was 47% (17-120%) of 
predicted. Overall, pirfenidone attenuated the decline in FVC (p=0.065), but did not 
influence the decline in DLCO (p=0.355) in comparison to the pre-treatment period. 
Stratification of patients according to %FVC level at baseline (>75% and ≤75%) and GAP 
index at baseline (stage I vs. II/III) showed that attenuation of decline in lung function 
was more pronounced in patients with more severe disease. The authors suggest that 
since pirfenidone was beneficial in patients with moderate-severe disease, it might also 
be effective in patients with more advanced disease [52]. 
 
Because IPF is a highly heterogeneous disease with variable disease course, obtaining 
accurate data from individual clinical trials enrolling limited numbers of patients is 
challenging. Pooling and analysing data from trials with similar design, patient 
populations and outcomes, enables clinicians to obtain greater insight into the effects 
of a given therapy. Noble et al. and Nathan et al. published the results of pooled 
analyses of the two CAPACITY trials and the ASCEND trial [53,54]. The Noble analysis 
included 1247 patients randomised to pirfenidone 2403/mg/day or placebo in the 
CAPACITY or ASCEND studies. At 1 year, pirfenidone reduced the proportion of patients 
with a ≥10% decline FVC % Pred or death by 43.8% (95% CI 29.3–55.4%) and increased 
the proportion of patients with no decline by 59.3% (95% CI 29.0–96.8%). A treatment 
benefit was also observed for progression-free survival, 6-min walk distance and 
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dyspnoea. Gastrointestinal and skin-related adverse events were more common in the 
pirfenidone group, but rarely led to discontinuation. The authors concluded that results 
provide the most stable and robust estimates to date of the magnitude of the 
treatment effect of pirfenidone on multiple measures of IPF disease progression and 
provide further evidence to support the clinically meaningful treatment benefit and 
acceptable safety profile of pirfenidone in patients with IPF. Similarly Nathan et al 
concluded that pirfenidone is associated with a reduction in the relative risk of 
mortality compared with placebo over 120 weeks [54]. Albera et al. in a post-hoc 
analysis of the same patient group showed efficacy of pirfenidone in patients both with 
more preserved lung function (FVC ≥80% or GAP stage I) and well as in those with less 
preserved lung function (FVC <80% or GAP stage II-III), supporting the initiation of 
treatment with pirfenidone, irrespective of stage of baseline lung function [55].  
 
Nintedanib (Ofev®; Boehringer Ingelheim, Germany), a tyrosine kinase inhibitor that 
targets the PDGF receptors α/β, FGF receptors 1 to 3, and VEGF receptors 1-3, is 
approved in the USA and the EU for the treatment of IPF [1,56,57]. Nintedanib is 
available in Italy with the name Ofev® [58]. The efficacy and safety of nintedanib has 
been confirmed in three landmark international phase II/III placebo controlled trials in 
patients with IPF and more recently in subgroup analyses and pooled/meta-analyses 
[59-62]. In the TOMORROW phase II, placebo-controlled, 52-week, dose-finding trial, 
428 patients with IPF were randomized to one of four doses of nintedanib (50mg daily, 
50mg bid, 100mg bid, or 150mg bid) using a stepwise increasing dose approach [59]. 
Nintedanib (150mg bid) reduced the annual rate of decline of FVC and lowered the 
incidence of acute exacerbations compared with placebo with an acceptable safety and 
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tolerability profile [59].  
 
Following the encouraging results of the TOMORROW trial, two replicate randomised, 
placebo-controlled, 52-week phase III studies – the INPULSIS® trials – were conducted 
[61]. Patients were randomized to receive nintedanib 150mg bid (309 patients in 
INPULSIS-1 and 329 in INPULSIS-2) or placebo (204 patients in INPULSIS-1 and 219 in 
INPULSIS-2). In both trials nintedanib significantly reduced the annual rate of decline in 
FVC compared with placebo. In INPULSIS®-2, there was a significant difference in favour 
of nintedanib on time to first acute exacerbation and change from baseline in SGRQ (St. 
George's Respiratory Questionnaire total score, a measure of QoL). The tolerability of 
nintedanib was manageable for most patients, Among the patients in the nintedanib 
groups who had diarrhoea, most reported events that were of mild or moderate 
intensity (93.7% in INPULSIS-1 and 95.2% in INPULSIS-2). 
 
The similar design of the TOMORROW and INPULSIS trials and the consistent results 
observed on the primary endpoint meant that data from these three trials (1231 
patients: 723 nintedanib, 508 placebo), could be combined (pooled and meta-analyses) 
to determine the overall efficacy and safety of nintedanib (150mg bid) [61,63]. In 
general, treatment effect sizes were similar across the pooled and meta-analyses. 
Nintedanib consistently slowed disease progression by significantly reducing the annual 
rate of decline in FVC compared with placebo [64]. In the pooled analysis, the hazard 
ratio (HR) for time to first acute exacerbation was 0.53 ([95% CI: 0.34, 0.83]; p=0.0047), 
in favour of nintedanib. The proportion of patients with 1 acute exacerbation was 4.6% 
in the nintedanib group and 8.7% in the placebo group [62]. Importantly, an analysis of 
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deaths occurring between randomization and the end of the follow-up period (28 days 
after last study drug intake in the INPULSIS trials and a maximum of 14 days after last 
study drug intake in the TOMORROW trial), showed a significant 43% reduction in risk 
in favour of nintedanib (HR: 0.57;95% CI: 0.34–0.97; p = 0.0274) [57]. A 30% reduction 
in the risk of all-cause mortality was observed with nintedanib versus placebo over 52 
weeks (HR 0.70 [95% CI: 0.46, 1.08]; p=0.0954). Overall the percentage of patients who 
died from a respiratory cause was 3.6% and 5.7% in the nintedanib and placebo groups, 
respectively [62]. 
 
Post-hoc subgroup analyses from the pooled INPULSIS® clinical trials demonstrated a 
consistent effect of nintedanib in patients with different degrees of lung function 
impairment and different radiologic patterns in imaging tests at baseline (no 
honeycombing and no confirmation of diagnosis in lung biopsy vs. patients with 
honeycombing and/or biopsy confirmation of diagnosis) [56,65]. The most frequently 
reported adverse event in the INPULSIS® trials was diarrhoea (reported in 62% of 
patients compared with 18% with placebo) that led to premature treatment 
discontinuation in fewer than 5% of nintedanib-treated patients [61]. More than 90% 
of eligible patients (734/807) chose to receive open-label nintedanib in the on-going 
INPULSIS®-ON extension trial. A recent interim analysis confirmed the long-term 
efficacy and safety of nintedanib, with the beneficial effect of nintedanib on slowing 
disease progression maintained in the long-term and the change from baseline in FVC 
consistent over 2 years. The INPULSIS® trials enrolled a wide range of patients including 
those with mild FVC impairment at baseline (FVC >90% predicted) and the proven clini-
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cal efficacy of nintedanib in slowing disease progression emphasizes the important of 
early preventive care with an effective symptom-based treatment. 
 
6.1 A multidisciplinary team approach to optimise diagnosis and management of 
patients with idiopathic pulmonary fibrosis 
It is universally accepted that the accuracy of the diagnosis of IPF increases when a 
MDT is involved. Accordingly, the international guidelines on the diagnosis and 
management of IPF state ‘careful exclusion of alternative aetiologies through a 
multidisciplinary discussion (MDD) between pulmonologists, radiologists, and 
pathologists experienced in the diagnosis of ILD is of the utmost importance to an 
accurate diagnosis’ in particular in those cases where the radiological patterns do not 
agree [2]. A diagnosis made by a MDT after exchange of clinical, radiographic 
information, often differs from the initial diagnosis made by an individual team 
member working alone and that interaction between clinicians, radiologists, and 
pathologists improves diagnostic confidence [66,67]. Delayed access to a specialist 
centre was associated with higher mortality in IPF, independently of disease severity 
[47]. Ultimately, correct and early diagnosis of IPF cannot ignore the collaboration of 
general practitioners as the first port of call for patients with nonspecific symptoms.  
 
In our survey most patients (41%) were referred to our specialist centres by other 
respiratory pulmonologists; 18.0% presented at our centres as a first visit due 
symptoms; 7% were referred by a general practitioner; 13% by a radiologist and 6% by a 
cardiologist.  All of the ten Italian centres surveyed had the possibility of consultation 
with a MDT composed (variably) of pulmonologists, radiologists, thoracic surgeons, 
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cardiologists, immunologists, rheumatologists and pathologists on an impromptu basis 
and in only 3/10 centres there was a formalised MDT. Encouragingly our survey showed 
the majority of centres (6/10) actively collaborate with other centres of excellence in 
Italy but in only 4/10 centres there was an active patient organisation.  
 
Input from the MDT is vital in obtaining an early and accurate diagnosis, which is in 
turn essential to initiate therapies that have the potential to reduce disease 
progression. It should be remembered however that the role of the MDT does not stop 
with the diagnosis but is important at all stages of the disease from diagnosis through 
to treatment and eventually the palliative phase. Clinical signs and symptoms change 
over time and it is only by constant vigilance and re-evaluation that the efficacy of 
management strategies is ensured. Also the composition of the MDT should not be 
fixed over time, as the specialist skills necessary at the diagnostic phase are different 
from those at the palliative phase. To take one example — patients and patient groups 
often iterate that travelling long distances to specialist centres becomes increasingly 
difficult for patients with deteriorating respiratory function, so wherever possible, 
shared care between local and specialist centres should be provided and the MDT 
should include healthcare professionals experienced in palliative care. Likewise, in view 
of the impact of IPF diagnosis and prognosis it is important not to underestimate that 
patients and caregivers may require psychological support. Most centres in Italy 
already use the MDT approach but often this is on an ad hoc basis and is not a 
formalised part of patient care as resources are limited.   
 
6.1.1 Lung transplantation — a neglected area 
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In patients with IPF, lung transplantation reduces the risk of death by 75% compared 
with patients who remain on the waiting list and transplantation is a recognized 
therapeutic option for patients with IPF, representing 35% of transplant recipients. 
Current outcomes in lung transplantation for IPF show significant survival benefits with 
1-, 5-, and 10-year survival rates 74%, 45%, and 22%, respectively [68]. Although, these 
survival rates are significantly poorer than those for other causes of end stage lung 
disease, the possibility of lung transplantation should be taken into account when 
forming the MDT. It is also vital that an effective regional and national network is in 
place to make sure that patients with IPF are given the possibility of a lung transplant. 
 
As new therapies for IPF emerge a more patient-centred approach becomes more than 
a priority. Patient groups and not-for-profit organizations play a key role in providing 
information and resources but also in raising awareness of the disease at an 
administrative level. Feedback we receive from patients and their families indicate that 
there is an urgent need for more healthcare support and education including prompt 
referral to specialist centres and timely diagnosis. 
 
7.1 Conclusion 
After many years in the wilderness IPF is getting the attention it deserves – valid 
therapeutic options with demonstrated efficacy in slowing the decline in lung function 
are available for patients with IPF. The importance of an early and accurate diagnosis of 
IPF cannot be underestimated and it is the duty of all healthcare professionals to be 
vigilant to the symptoms of IPF and to involve a MDT in diagnosing and managing IPF 
early in the course of disease. 
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Our experience in Italy confirms published data showing that there are still large unmet 
medical, social and economic needs [69]. Left untreated IPF is an extremely debilitating 
disease and one that patients struggle to understand fully. The first challenge to 
address is increasing patient and physician knowledge of IPF. From the outset, patients, 
their families and their advocates need to be given clear and consistent information on 
the course, management, and care of their condition. Academic and practicing 
physicians need to work together to better define and disseminate information about 
IPF and to motivate providers to provide the necessary resources to ensure timely 
diagnosis and effective management of IPF. 
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